Inc to "neutral" from "overweight" on Wednesday, citing concerns over waning growth prospects as subscription revenue and ...

U.S. Treasury yields are inching higher after Monday’s drop, as investors navigate the holiday-shortened trading week. But ...

In a report released today, Thomas Champion from Piper Sandler maintained a Buy rating on Amazon (AMZN – Research Report), with a price target ...

We recently published a list of 15 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced ...

Piper Sandler lowered the firm’s price target on CVS Health (CVS) to $64 from $72 and keeps an Overweight rating on the ...

Piper Sandler analyst Brent Bracelin raised the firm’s price target on Procore (PCOR) to $90 from $70 and keeps an Overweight ...

Piper Sandler currently has a neutral rating on the stock. Several other research analysts also recently commented on the company. Barclays reduced their target price on Stem from $4.00 […] ...

today announced that management will participate in a fireside chat at the Piper Sandler 36 th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time. A live audio webcast ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare ...

Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are ...

NEWTON, Mass., Nov. 25, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the ...